Could a diabetes pill lift bipolar depression? small study aims to find out
NCT ID NCT07472920
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether empagliflozin, a drug used for diabetes, can help reduce depression in people with bipolar disorder who also have insulin resistance. Twenty adults with bipolar depression will take the drug for 12 weeks alongside their usual treatment. The goal is to see if improving insulin resistance can improve mood and guide future research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Psychiatry, University of São Paulo Medical School (IPq-FMUSP)
São Paulo, São Paulo, 05403-903, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a traditional herbal remedy tame type 2 diabetes?
- Can a single psychedelic dose rewire the depressed brain?
- Can decades of lifting weights keep the Brain's muscle signals young?
- Can a web app get people moving in mental health residential care?
- Can brain implants read and treat bipolar depression without triggering mania?
- Smartwatch data may forecast bipolar mood swings